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aBstraCt
introduCtion. The aim of the study was to evaluate the retinal nerve fibre layer (RNFL) thickness loss in primary 
open-angle glaucoma (POAG) patients treated topically with anti-glaucoma drops containing brimonidine and 
timolol combination or solely timolol.
MateriaLs and Methods. Retrospective case series study of patients with POAG diagnosis followed up for 
a five-year period. Inclusion criteria were fulfilled by a group of 98 patients consisting of 53 combination and 
45 monotherapy treatments. Intraocular pressure (IOP) at the level of 21 mm Hg or below for each measurement 
was observed in 52 patients, while incidences of pressure above 21 mm Hg were measured in 46 patients. POAG 
diagnosis was based on standard optical coherence tomography, IOP, and visual field examinations.
resuLts. Mean annual loss of RNFL thickness in the overall study group (if IOP levels are not taken into consid-
eration) treated with timolol monotherapy was 1.8 ± 1.5 μm, while in group treated with brimonidine + timolol 
combination therapy it was 1.7 ± 1.5 μm (p > 0.05). In selected groups of patients with incidents of pressure rises, 
the mean annual loss of retinal nerve fibre layer thickness was 1.8 ± 1.6 and 1.9 ± 1.4 μm, respectively, for the mon-
otherapy and combination therapy groups (p > 0.05). In the group of patients with no reported IOL rises, mean 
annual loss of RNFL thickness was 1.8 ± 0.9 and 1.1 ± 0.4 μm, respectively, for the monotherapy and combination 
therapy groups (p < 0.01). No significant differences were observed for the visual field mean deviation.
ConCLusions. POAG patients with low values of IOP might achieve slower progression of RNFL thinning on 
brimonidine combined with timolol therapy.
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introduCtion
According to the World Health Organization, glau-
coma is the second most common cause of blindness 
worldwide [1]. A basic measurable pathogenic factor 
of glaucomatous injury to the optic nerve is increased 
intraocular pressure (IOP), which is associated with 
70% of cases [2, 3].
Current glaucoma treatment focuses only on 
lowering the increased IOP; however, active research 
is taking place of mechanisms that evoke retinal 
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ganglion cell (RGC) damage aiming to find a new 
neuroprotective target to prevent blindness [4]. Bri-
monidine, a2-adrenergic receptor agonist, has been 
documented to have neuroprotective potential un-
der experimental conditions, while clinical trials do 
not unequivocally support this discovery [4–9].
We report a five-year retrospective analysis of 
retinal nerve fibre layer (RNFL) thickness, IOP, 
and visual field (VF) of primary open angle glau-
coma (POAG) patients treated with either topical 
brimonidine/timolol combination therapy or solely 
with timolol.
MateriaLs and Methods
A five-year retrospective analysis of 1800 POAG 
patients was performed, from among of which we 
selected patients fulfilling the inclusion criteria: 
availability of annual ocular coherence tomography 
(OCT) data (TD-OCT Stratus; Carl Zeiss Med-
itec, Dublin, CA, USA) and VF (30-2 Humphrey 
test, Humphrey 740, Carl Zeiss Meditec, Dublin, 
CA, USA) for five years, at least three annual IOP 
measurements (Goldmann Applanatory Tonometer, 
GAT, Haag-Streit AG, Switzerland), and continu-
ous five-year treatment with either a combination 
of topical brimonidine + timolol (Combigan, Aller-
gan, Irvine, CA, USA) or solely with timolol (Of-
tensin 0.5%, Polpharma, Warsaw, Poland). Based 
on the above criteria, 98 patients (69 females and 
29 males, in the age range 38 to 89 years) were in-
cluded in study group. All patients’ mean five-year 
IOP was below the normative 21 mm Hg; how - 
e ver, we observed patients who tended to have sin-
gle, short-lasting IOP elevations above 21 mm Hg. 
Patients were divided into the following groups: 
group BT (n = 53 patients, 104 eyes) — all patients 
treated with brimonidine + timolol combination 
therapy; group T (n = 45 patients, 89 eyes) — all pa-
tients treated with timolol monotherapy; group BT– 
(n = 32 patients, 63 eyes) — brimonidine + tim-
olol combination therapy with no IOP increase 
above 21 mm Hg during follow-up time; group T– 
(n = 20 patients, 40 eyes) — timolol monotherapy 
with no IOP increase above of 21 mm Hg during 
follow-up time; group BT+ (n = 21 patients, 41 eyes) 
— brimonidine/timolol combination therapy with 
IOP rise above 21 mm Hg during follow-up time; 
and group T+ (25 patients, 49 eyes) — timolol mono-
therapy with IOP rise above 21 mm Hg during fol-
low-up. Progression of glaucoma in all patients was 
apparent when examined with OCT (RNFL thin-
ning) as well as with VF (MD defect). Treatment 
was constant for the entire five-year period. The 
normative IOP was defined as less than 21 mm Hg 
and IOP elevation as above 21 mm Hg.
resuLts
Mean five-year IOP values, as well as input 
RNFL thickness, were not significantly different 
between groups (p > 0.05, Mann Whitney U-test; 
Tab. 1). No statistically significant differences for 
the mean values of MD, mean final RNFL thick-
ness, loss of RNFL thickness, or the annual rate of 
loss (p > 0.05, Mann Whitney U-test) were seen 
between groups BT and T (Tab. 1; Fig. 1 A–C). 
In these groups the presence of reported increases 
of IOP above 21 mm Hg affected RNFL thickness 
(p < 0.03, Mann Whitney U-test). Therefore, over-
all patients’ groups were divided into subgroups 
with or without reported single IOP rises.
groups With reported iop eLeVations
No statistical significance between the BT+ and T+ 
groups was observed for mean values of the MD 
change, the mean final RNFL thickness, the loss of 
RNFL thickness, or the annual rate of loss (p > 0.05, 
Mann-Whitney U-test) (Tab. 1; Fig. 1 D–F).
groups With no reported iop eLeVations
In contrast to the group with reported IOP in-
crease, the group with no single IOP elevations above 
21 mm Hg (group BT– vs. group T–) showed sta-
tistically significant differences in the loss of RNFL 
thickness, the annual rate of RNFL loss (p < 0.01, 
Mann-Whitney U test), and the mean final RNFL 
thickness (p < 0.05, Mann-Whitney U test) but no 
difference in the mean MD change during follow-up 
time (p > 0.05, Mann-Whitney U test) (Tab. I; Fig. 1 
G–I). Interestingly, thinning of RNFL was signifi-
cantly lower in patients without any reported eleva-
tions above the normative 21 mm Hg, if treatment 
with combination brimonidine + timolol therapy was 
applied, rather than if only timolol therapy was used.
disCussion
In this report, we showed limited morphologi-
cal, but not functional, neuroprotective effect over 
a five-year period of topical brimonidine + timolol 
compared with timolol, administered twice daily in 
primary open-angle glaucoma patients, which was 
shown in reduced thinning of RNFL, but not in the 
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Table I. Mean ± standard deviation (SD) values of intraocular pressure (IOP), retinal nerve fibre layer (RNFL), 
and visual field mean deviation (MD) in subgroups
Group IOP
[mm Hg]
MD change 
[dB]
Output RNFL 
thickness 
[µm]
Final RNFL 
thickness 
[µm]
RNFL loss 
[µm]
Annual 
RFNL loss 
[µm/year]
BT (brimonidine + timolol) 17.3 ± 3.9 2.5 ± 0.5 74.0 ± 20.0 66.1 ± 14.1 7.9 ± 4.3 1.7 ± 1.5
T (timolol) 16.3 ± 3.6 1.3 ± 0.7 74.9 ± 15.4 65.7 ± 12.9 9.2 ± 5.6 1.8 ± 1.5
BT+ (brimonidine + timolol) 18.6 ± 4.4 2.8 ± 1.4 71.9 ± 19.9 62.3 ± 10.7 9.6 ± 7.2 1.9 ± 1.4
T+ (timolol) 18.3 ± 5.1 1.9 ± 0.8 71.3 ± 17.6 62.1 ± 11.5 9.2 ± 7.9 1.8 ± 1.6
BT– (brimonidine + timolol) 15.1 ± 1.5 2.1 ± 1.5 77.8 ± 20.5 72.7 ± 18.3 5.1 ± 1.8 1.1 ± 0.4
T– (timolol) 15.4 ± 1.9 1.0 ± 0.9 76.2 ± 13.7 67.0 ± 12.8 9.2 ± 2.4 1.8 ± 0.9
BT+ — brimonidine + timolol group with IOP spikes; BT- — brimonidine + timolol group with no IOP spikes; T- — timolol group with no IOP spikes; T+ — timolol group with IOP spikes
Figure 1. Comparison between study groups for retinal nerve fibre layer (RNFL) derived from ocular coherence tomography (OCT) and mead 
deviation (MD) derived from visual fields. a–C — comparison between group BT and T showed no statistical differences in MD changes, 
mean final RNFL thickness, and RNFL thickness loss rate. d–F — comparison between group BT+ and T+ showed no statistical differences in 
MD changes, mean final RNFL thickness, and RNFL thickness loss rate. g — comparison between group BT- and group T- showed no statisti-
cal differences in MD changes, but there was a significant difference in mean final RNFL thickness (h) and RFNL thickness loss rate (i) 
*Statistical significance; ns — not significant
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VF MD coefficient. Since no significant difference 
between IOP values in groups was observed, we es-
timate that the protective capacity of brimonidine 
is IOP-independent, although the exact molecular 
signalling mechanisms were not studied. In our study, 
patients with even single episodes of IOP rise above 
the normative 21 mm Hg did not show additional 
benefit from the brimonidine + timolol treatment, 
when compared to the timolol group. Other studies 
showed no evidence for the neuroprotective activity 
of brimonidine in patients with high-pressure acute 
angle closure glaucoma or high-pressure open-an-
gle glaucoma [10, 11]. Similarly, Tsai and Chang 
showed that patients with mean IOP < 21 mm Hg 
treated with brimonidine appear to have lower RNFL 
loss compared to patients treated with timolol over 
a 12-month period [10]. In a low-tension glaucoma 
study, Krupin et al. reported that patients treated with 
topical brimonidine were less likely to have visual field 
progression than patients treated with topical timolol 
only [9]. Similar observations were done by Evans et 
al. using contrast sensitivity test as a tool to evaluate 
visual function [7]. Sebastiani et al. and Wessel et 
al. independently documented that the mean annual 
RNFL thickness loss in glaucoma patients varies be-
tween 1.1 and 2.1 μm/year, while in healthy eyes the 
thickness loss is estimated to be 0.5–0.6 μm/year [12, 
13]. In our study, the mean RNFL loss varied between 
1.7 and 1.8 μm/year. It is known that IOP higher 
than 17 mm Hg induces an additional 0.05 μm/year 
RNFL loss for each increased 1 mm Hg [14, 15]. Sur-
prisingly, even single, short-lasting IOP peaks above 
21 mm Hg in our analysis, significantly decreased 
RNFL thickness, although mean IOP remained with-
in the normal levels. Thus, it might be essential to 
observe daily fluctuations, especially in glaucoma pa-
tients who show disease progression. Retinal thickness 
analysis with the time domain OCT is commonly 
considered to be less reliable compared with the spec-
tral domain OCT; however, numerous reports suggest 
that TD OCT is as reliable as SD OCT to measure 
RNFL thickness and glaucoma progression [15, 17].
ConCLusions
Our results revealed that topical combination of 
brimonidine and timolol rather than timolol only 
may have an additional neuroprotective capacity in 
certain POAG patients who might depend on the 
IOP spikes, and even short-lasting single elevations of 
IOP may accelerate RNFL thinning.
Conflict of interest: none declared
reFerenCes
1. Quigley HA, Broman AT. The number of people with glaucoma world-
wide in 2010 and 2020. Br J Ophthalmol. 2006; 90(3): 262–267, 
doi: 10.1136/bjo.2005.081224, indexed in Pubmed: 16488940.
2. Casson RJ. Pathogenesis of primary open-angle glaucoma. Clin Exp 
Ophthalmol. 2012; 40(9): 838–839, doi: 10.1111/ceo.12013, indexed 
in Pubmed: 23217143.
3. Musch DC, Gillespie BW, Niziol LM, et al. CIGTS Study Group. Intraocular 
pressure control and long-term visual field loss in the Collaborative Initial 
Glaucoma Treatment Study. Ophthalmology. 2011; 118(9): 1766–1773, 
doi: 10.1016/j.ophtha.2011.01.047, indexed in Pubmed: 21600658.
4. Danesh-Meyer HV. Neuroprotection in glaucoma: recent and future 
directions. Curr Opin Ophthalmol. 2011; 22(2): 78–86, doi: 10.1097/
ICU.0b013e32834372ec, indexed in Pubmed: 21252670.
5. Hernández M, Urcola JH, Vecino E. Retinal ganglion cell neuroprotection 
in a rat model of glaucoma following brimonidine, latanoprost or com-
bined treatments. Exp Eye Res. 2008; 86(5): 798–806, doi: 10.1016/j.
exer.2008.02.008, indexed in Pubmed: 18394603.
6. Saylor M, McLoon LK, Harrison AR, et al. Experimental and clinical 
evidence for brimonidine as an optic nerve and retinal neuropro-
tective agent: an evidence-based review. Arch Ophthalmol. 2009; 
127(4): 402–406, doi: 10.1001/archophthalmol.2009.9, indexed in 
Pubmed: 19365015.
7. Evans DW, Hosking SL, Gherghel D, et al. Contrast sensitivity improves 
after brimonidine therapy in primary open angle glaucoma: a case for 
neuroprotection. Br J Ophthalmol. 2003; 87(12): 1463–1465, indexed 
in Pubmed: 14660453.
8. Cantor LB, Safyan E, Liu CC, et al. Brimonidine in the treatment of 
glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006; 2(4): 
337–346, indexed in Pubmed: 18360646.
9. Krupin T, Liebmann JM, Greenfield DS, et al. Low-Pressure Glaucoma 
Study Group. A randomized trial of brimonidine versus timolol in preserv-
ing visual function: results from the Low-Pressure Glaucoma Treatment 
Study. Am J Ophthalmol. 2011; 151(4): 671–681, doi: 10.1016/j.
ajo.2010.09.026, indexed in Pubmed: 21257146.
10. Tsai JC, Chang HW. Comparison of the effects of brimonidine 0.2% 
and timolol 0.5% on retinal nerve fiber layer thickness in ocular hyper-
tensive patients: a prospective, unmasked study. J Ocul Pharmacol 
Ther. 2005; 21(6): 475–482, doi: 10.1089/jop.2005.21.475, indexed 
in Pubmed: 16386089.
11. Aung T, Oen FTS, Wong HT, et al. Randomised controlled trial comparing 
the effect of brimonidine and timolol on visual field loss after acute 
primary angle closure. Br J Ophthalmol. 2004; 88(1): 88–94, indexed 
in Pubmed: 14693782.
12. Costagliola C, Parmeggiani F, Ciancaglini M, et al. Effects of acute topical 
administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 
0.2% on visual field parameters and ocular perfusion pressure in patients 
with primary open-angle glaucoma. Acta Ophthalmol Scand Suppl. 
2002; 236(1): 29–30, indexed in Pubmed: 12390124.
13. Wessel JM, Horn FK, Tornow RP, et al. Longitudinal analysis of progres-
sion in glaucoma using spectral-domain optical coherence tomography. 
Invest Ophthalmol Vis Sci. 2013; 54(5): 3613–3620, doi:  10.1167/
iovs.12-9786, indexed in Pubmed: 23633657.
14. Grewal DS, Sehi M, Paauw JD, et al. Advanced Imaging in Glaucoma 
Study Group. Detection of progressive retinal nerve fiber layer thickness 
loss with optical coherence tomography using 4 criteria for functional 
progression. J Glaucoma. 2012; 21(4): 214–220, doi: 10.1097/IJG.
0b013e3182071cc7, indexed in Pubmed: 21654510.
15. Medeiros F, Alencar L, Zangwill L, et al. The Relationship between 
Intraocular Pressure and Progressive Retinal Nerve Fiber Layer 
Loss in Glaucoma. Ophthalmology. 2009; 116(6): 1125–1133.e3, 
doi: 10.1016/j.ophtha.2008.12.062.
16. Chang RT, Knight OJ, Feuer WJ, et al. Sensitivity and specificity of 
time-domain versus spectral-domain optical coherence tomography 
in diagnosing early to moderate glaucoma. Ophthalmology. 2009; 
116(12): 2294–2299, doi:  10.1016/j.ophtha.2009.06.012, indexed 
in Pubmed: 19800694.
17. Takagishi M, Hirooka K, Baba T, et al. Comparison of retinal nerve fiber 
layer thickness measurements using time domain and spectral domain 
optical coherence tomography, and visual field sensitivity. J Glaucoma. 
2011; 20(6): 383–387, doi: 10.1097/IJG.0b013e3181efb371, indexed 
in Pubmed: 20717050.
